Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

mineralys therapeutics inc. - MLYS

MLYS

Close Chg Chg %
15.19 -0.08 -0.53%

Closed Market

15.11

-0.08 (0.53%)

Volume: 1.02M

Last Updated:

May 14, 2025, 4:00 PM EDT

Trade Now

Company Overview: mineralys therapeutics inc. - MLYS

MLYS Key Data

Open

$15.20

 Day Range

14.89 - 15.86

52 Week Range

8.24 - 18.37

 Market Cap

$990.01M

Shares Outstanding

65.18M

 Public Float

38.99M

Beta

-0.31

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$3.74

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

708.35K

  

MLYS Performance

1 Week
 
 3.69%
 
1 Month
 
 13.78%
 
3 Months
 
 48.34%
 
1 Year
 
 16.85%
 
5 Years
 
 N/A
 

MLYS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About mineralys therapeutics inc. - MLYS

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

MLYS At a Glance

Mineralys Therapeutics, Inc.
150 North Radnor Chester Road
Radnor, Pennsylvania 19087
Phone 1-888-378-6240 Revenue 0.00
Industry Biotechnology Net Income -177,810,000.00
Sector Health Technology Employees 51
Fiscal Year-end 12 / 2025
View SEC Filings

MLYS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 3.207
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.076
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

MLYS Efficiency

Revenue/Employee N/A
Income Per Employee -3,486,470.588
Receivables Turnover N/A
Total Asset Turnover N/A

MLYS Liquidity

Current Ratio 14.021
Quick Ratio 14.021
Cash Ratio 13.532

MLYS Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -77.725
Return on Equity -82.241
Return on Total Capital -92.969
Return on Invested Capital -82.241

MLYS Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Mineralys Therapeutics Inc. - MLYS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
- - - 43.00K
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - - 43.00K
-
Depreciation
- - - 43.00K
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - -
-
Gross Income
- - - (43.00K)
-
Gross Income Growth
- - - -
-
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
18.73M 31.48M 84.66M 192.36M
Research & Development
16.31M 26.25M 70.36M 168.58M
Other SG&A
2.42M 5.23M 14.30M 23.78M
SGA Growth
+536.26% +68.11% +168.93% +127.22%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 657.00K
-
EBIT after Unusual Expense
(19.38M) (31.48M) (84.66M) (192.40M)
Non Operating Income/Expense
1.00K 1.68M 12.76M 14.59M
Non-Operating Interest Income
- 1.68M 12.76M 14.59M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 27.00K
-
Interest Expense Growth
- - -76.52% -100.00%
-
Gross Interest Expense
- - - 27.00K
-
Interest Capitalized
- - - -
-
Pretax Income
(19.41M) (29.80M) (71.90M) (177.81M)
Pretax Income Growth
-466.49% -53.54% -141.28% -147.31%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(19.41M) (29.80M) (71.90M) (177.81M)
Minority Interest Expense
- - - -
-
Net Income
(19.41M) (29.80M) (71.90M) (177.81M)
Net Income Growth
-466.49% -53.54% -141.28% -147.31%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(19.41M) (29.80M) (71.90M) (177.81M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(19.41M) (29.80M) (71.90M) (177.81M)
EPS (Basic)
-0.3606 -0.7294 -1.9868 -3.6632
EPS (Basic) Growth
-426.42% -102.27% -172.39% -84.38%
Basic Shares Outstanding
53.82M 40.86M 36.19M 48.54M
EPS (Diluted)
-0.3606 -0.7294 -1.9868 -3.6632
EPS (Diluted) Growth
-426.42% -102.27% -172.39% -84.38%
Diluted Shares Outstanding
53.82M 40.86M 36.19M 48.54M
EBITDA
(18.73M) (31.48M) (84.66M) (192.36M)
EBITDA Growth
-536.26% -68.11% -168.93% -127.22%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 40.00
Number of Ratings 7 Current Quarters Estimate -0.753
FY Report Date 06 / 2025 Current Year's Estimate -3.285
Last Quarter’s Earnings -0.79 Median PE on CY Estimate N/A
Year Ago Earnings -3.66 Next Fiscal Year Estimate -3.335
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 6 6
Mean Estimate -0.75 -0.76 -3.29 -3.34
High Estimates -0.60 -0.55 -2.43 -2.32
Low Estimate -0.86 -0.92 -4.42 -4.53
Coefficient of Variance -18.52 -22.61 -22.54 -26.74

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 8 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Mineralys Therapeutics Inc. - MLYS

Date Name Shares Transaction Value
Mar 14, 2025 David M. Rodman Chief Medical Officer 170,869 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.08 per share 184,538.52
Mar 14, 2025 David M. Rodman Chief Medical Officer 115,880 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 13, 2024 David M. Rodman Chief Medical Officer 20,069 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 13, 2024 David M. Rodman Chief Medical Officer 170,786 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 21, 2024 Jon Congleton Chief Executive Officer; Director 958,505 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.25 per share 11,741,686.25
Jun 21, 2024 Jon Congleton Chief Executive Officer; Director 941,898 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.99 per share 11,293,357.02
Jun 21, 2024 Jon Congleton Chief Executive Officer; Director 926,958 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.73 per share 10,873,217.34
Jun 18, 2024 Alexander M. Gold Director 44,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 14, 2024 Adam S. Levy CFO and Secretary 255,462 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.94 per share 3,305,678.28
May 29, 2024 Derek DiRocco Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Srinivas Akkaraju Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Glenn P. Sblendorio Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Daphne Karydas Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Olivier Litzka Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Catalys Pacific LLC Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Mineralys Therapeutics Inc. in the News